Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
AAPS PharmSciTech. 2022 Feb 17;23(3):76. doi: 10.1208/s12249-022-02220-0.
The preparation of drugs into nanocrystals represents a practical pharmaceutical technology to solubilize poorly water-soluble drugs and enhance bioavailability. However, commonly used stabilizers in nanocrystals like polymers and surfactants are frequently inefficient and cannot stabilize nanocrystals for an expected time. This study reports an exquisite platform for nanocrystal production based on a metal-phenolic network (MPN). MPN-wrapped nanocrystal particles (MPN-NPs) were fabricated through an anti-solvent precipitation method using tannic acid and Fe or Al as coupling agents and characterized by dynamic light scattering, transmission electron microscope, ultraviolet and visible spectrophotometry, fourier-transform infrared spectroscopy, and X-ray powder diffraction. In vitro release, cytotoxicity, and stability were mainly studied with MPN-NPs loading paclitaxel. The suitability of MPN as a nanocrystal stabilizer was also investigated for other classical hydrophobic drugs, including simvastatin, andrographolide, atorvastatin calcium, ferulic acid, and famotidine. The results showed that MPN could effectively wrap and stabilize various drug nanocrystals apart from famotidine. The maximum solubilization of MPN towards atorvastatin calcium was up to 1587 folds, and it also exhibited an excellent solubilizing effect on other hydrophobic drugs. We disclosed that the drug was entrapped in MPN in the nanocrystal form, and there were distinct physiochemical interactions between MPN and the payload. Our findings suggested that MPN may be a promising platform for nanocrystal production to address the challenge of low solubility associated with hydrophobic drugs. Graphical abstract.
药物制备成纳米晶体代表了一种实用的制药技术,可以溶解水溶性差的药物并提高生物利用度。然而,纳米晶体中常用的稳定剂,如聚合物和表面活性剂,通常效率不高,无法在预期的时间内稳定纳米晶体。本研究报告了一种基于金属-酚网络(MPN)的纳米晶体生产的精致平台。MPN 包裹的纳米晶体颗粒(MPN-NPs)是通过单宁酸和 Fe 或 Al 作为偶联剂的反溶剂沉淀法制备的,并通过动态光散射、透射电子显微镜、紫外可见分光光度法、傅里叶变换红外光谱和 X 射线粉末衍射进行了表征。主要研究了 MPN-NPs 负载紫杉醇的体外释放、细胞毒性和稳定性。还研究了 MPN 作为纳米晶体稳定剂的适宜性,用于其他经典疏水性药物,包括辛伐他汀、穿心莲内酯、阿托伐他汀钙、阿魏酸和法莫替丁。结果表明,MPN 可以有效地包裹和稳定各种药物纳米晶体,除了法莫替丁。MPN 对阿托伐他汀钙的最大增溶倍数高达 1587 倍,对其他疏水性药物也表现出优异的增溶效果。我们揭示了药物以纳米晶体的形式被包埋在 MPN 中,MPN 和有效载荷之间存在明显的物理化学相互作用。我们的研究结果表明,MPN 可能是一种有前途的纳米晶体生产平台,可以解决与疏水性药物相关的低溶解度挑战。